

Additional file 5: Effect of statin according to trial duration. Most frequently used dose in the trials

Atorvastatin 10 mg

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|-----------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 4 | 1107 | 1107 | All combined | 12-52 wks | 7.2 | -2.0 | -27 |
| 3 | 975 | 975 | 12-24 wks | 12-16 wks | 7.1 | -1.9 | -27 |
| 1 | 132 | 132 | 25-52 wks | 52 wks | 7.6 | -2.3 | -30 |

Cerivastatin 0.4 mg

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|-----------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 2 | 527 | 527 | All combined | 24/52 wks | 7.0 | -1.7 | -25 |
| 1 | 332 | 332 | 12-24 wks | 24 wks | 6.8 | -1.8 | -26 |
| 1 | 195 | 195 | 25-52 wks | 52 wks | 7.2 | -1.7 | -24 |

Fluvastatin 40 mg

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|-----------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 5 | 376 | 376 | All combined | 12-24 wks | 7.6 | -1.3 | -17 |
| 3 | 122 | 122 | 12 wks | 12 wks | 6.8 | -1.5 | -20 |
| 2 | 254 | 254 | 24 wks | 24 wks | 7.4 | -1.3 | -17 |

Lovastatin 40 mg

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|-----------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 4 | 3743 | 3743 | All combined | 12-48 wks | 6.8 | -1.5 | -23 |
| 2 | 387 | 387 | 12-24 wks | 12-14 wks | 7.8 | -1.6 | -21 |
| 2 | 3436 | 3436 | 25-52 wks | 48 wks | 6.7 | -1.5 | -22 |

Pravastatin 40 mg

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|----------------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 17 | 8716 | 6635 | All combined | 12 wks - 5 yrs | 6.5 | -1.3 | -21 |
| 11 | 2293 | 2293 | 12-24 wks | 12-24wks | 6.6 | -1.3 | -20 |
| 1 | 199 | 199 | 25-52 wks | 46 wks | 6.9 | -1.5 | -22 |
| 7 | 6674 | 4593 | > 1 yr | 2-5 yrs | 6.4 | -1.3 | -20 |

Rosuvastatin 5 or 10 mg

| Dose | Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|-------|------------------|--------------------|----------|--------------------|--------|-----------------------------|------------------------------------|---------|
| | | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 5 mg | 4 | 510 | 510 | 12 wks | 12 | 7.3 | -2.2 | -30 |
| 10 mg | 4 | 495 | 495 | 12 wks | 12 | 7.0 | -2.3 | -33 |

No data provided for total cholesterol over 52 weeks

Simvastatin 40 mg

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|------------------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 4 | 10952 | 10952 | All combined | 24 wks - 3.5 yrs | 5.7 | -1.5 | -26 |
| 2 | 477 | 477 | 12-24 wks | 24 wks | 8.0 | -2.4 | -31 |
| 2 | 10475 | 10475 | > 1 yr | 3-3.5 yrs | 5.6 | -1.5 | -26 |

Placebo

| Number of trials | Number of patients | | Duration | | Weighted mean initial [TC]* | Weighted mean change from baseline | |
|------------------|--------------------|----------|--------------------|----------------|-----------------------------|------------------------------------|---------|
| | Randomised | Analysed | Split for analysis | Actual | | Absolute | Percent |
| 47 | 25081 | 22617 | All combined | 12 wks - 5 yrs | 6.2 | 0.004 | -0.1 |
| 21 | 2090 | 2090 | 12-24 wks | 12-24 wks | 6.6 | -0.05 | -0.8 |
| 10 | 2852 | 2852 | 25-52 wks | 25-52 wks | 6.6 | 0.02 | 0.3 |
| 16 | 20028 | 17564 | 3-5 yrs | 3-5 yrs | 6.1 | 0.01 | 0.2 |

* [TC]: mean concentration of total cholesterol, in mmol/L, at baseline